These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1282869)

  • 1. Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.
    Chrisp P; Faulds D
    Drugs; 1992 Dec; 44(6):993-1012. PubMed ID: 1282869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
    Reid JL; Panfilov V; MacPhee G; Elliott HL
    Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension.
    Benedict CR
    Curr Hypertens Rep; 1999 Aug; 1(4):305-12. PubMed ID: 10981082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxonidine: pharmacology, clinical pharmacology and clinical profile.
    Elliott HL
    Blood Press Suppl; 1998; 3():23-7. PubMed ID: 10321451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.
    Bousquet P; Feldman J
    Drugs; 1999 Nov; 58(5):799-812. PubMed ID: 10595861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine.
    Rupp H; Maisch B; Brilla CG
    Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():251-62. PubMed ID: 8827948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with moxonidine.
    Prichard BN
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():49-58. PubMed ID: 8068579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxonidine: a new and versatile antihypertensive.
    Messerli F
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S53-6. PubMed ID: 11346219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharma-clinics. Medication of the month. Moxonidine (Moxon)].
    Scheen AJ
    Rev Med Liege; 2000 Jan; 55(1):61-3. PubMed ID: 10803041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxonidine for hypertension.
    Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.